Guangdong Jiaying Pharmaceutical Co., Ltd

Symbol: 002198.SZ

SHZ

6.73

CNY

Market price today

  • 121.8232

    P/E Ratio

  • 10.9641

    PEG Ratio

  • 3.42B

    MRK Cap

  • 0.00%

    DIV Yield

Guangdong Jiaying Pharmaceutical Co., Ltd (002198-SZ) Financial Statements

On the chart you can see the default numbers in dynamics for Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ). Companys revenue shows the average of 307.457 M which is 0.183 % gowth. The average gross profit for the whole period is 212.155 M which is 0.222 %. The average gross profit ratio is 0.632 %. The net income growth for the company last year performance is -0.219 % which equals 2.301 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Guangdong Jiaying Pharmaceutical Co., Ltd, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.001. In the realm of current assets, 002198.SZ clocks in at 580.174 in the reporting currency. A significant portion of these assets, precisely 334.037, is held in cash and short-term investments. This segment shows a change of 0.427% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 27.094, if any, in the reporting currency. This indicates a difference of -229.749% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 0 in the reporting currency. This figure signifies a year_over_year change of -1.000%. Shareholder value, as depicted by the total shareholder equity, is valued at 762.985 in the reporting currency. The year over year change in this aspect is 0.047%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 154.048, with an inventory valuation of 84.6, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 47.21.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004

balance-sheet.row.cash-and-short-term-investments

1231.73334234.1239.4
142.2
122.3
114.9
82
73.3
46.2
33.3
56.3
21.6
10.5
30.3
32.9
81.9
153.6
37.5
21.5
2.4

balance-sheet.row.short-term-investments

660.9200.550.30
0
-51.3
0
-0.3
-4.6
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

657.68154240.6175.7
218.5
202.7
237.9
246.7
250.6
211.2
194.7
159.8
42.8
35.4
34.9
39
70.4
31.8
25.4
11.8
5.2

balance-sheet.row.inventory

347.5884.682.373.4
72.8
76.8
71.7
63.3
48.2
47.4
60
55.6
24.4
24.1
16.5
8.4
7.7
8
6.7
7.9
10.6

balance-sheet.row.other-current-assets

5.961.10.41.2
1
7.5
-20.1
-19.8
-21.5
-11
16.1
0.2
-0.6
-1.3
-1
-0.3
-1.5
-3.5
-1.7
-0.9
-0.1

balance-sheet.row.total-current-assets

2267.86580.2557.4489.7
434.5
409.3
404.5
372.3
350.6
293.8
304
271.9
88.2
68.7
80.7
80
158.5
189.8
67.8
40.4
18.1

balance-sheet.row.property-plant-equipment-net

769.11190.4203.7224.2
245.8
255.6
252.2
265
261.3
275.1
245
200.8
146.5
152.4
156
128.2
72.2
50.5
46.4
45.3
47.7

balance-sheet.row.goodwill

0000
0
0
120.8
120.8
360.9
360.9
360.9
360.9
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

191.4647.252.458.3
64.2
69.5
75.3
81.2
87.1
93
97.4
75.3
3.6
4.2
4.8
5.4
4.4
5.1
5.8
5.5
6.1

balance-sheet.row.goodwill-and-intangible-assets

191.4647.252.458.3
64.2
69.5
196.1
202
448
453.9
458.3
436.2
3.6
4.2
4.8
5.4
4.4
5.1
5.8
5.5
6.1

balance-sheet.row.long-term-investments

-134.0927.1-20.930.6
58.3
113.3
27.6
26.3
25.8
16.5
8.8
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

8.722.22.24.6
5.6
5
8.7
8.7
8.4
6.9
4.6
4.1
1.3
0.5
0.3
0.1
0.2
0.1
0.1
0
0

balance-sheet.row.other-non-current-assets

240.920.551.80
0.1
3.4
0.5
2.3
5.1
1.7
14.6
6
74.7
80.8
59.1
39.6
0
0
0
0
0

balance-sheet.row.total-non-current-assets

1076.11267.4289.2317.7
373.9
446.7
485.1
504.4
748.6
754.2
731.3
647.1
226
237.8
220.1
173.4
76.8
55.6
52.2
50.9
53.8

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

3343.97847.6846.7807.3
808.4
855.9
889.6
876.6
1099.3
1048
1035.3
919
314.2
306.5
300.9
253.3
235.2
245.5
120.1
91.2
71.9

balance-sheet.row.account-payables

42.139.21914.1
10.3
15.6
10.2
11.9
11.2
12.3
66.3
17.4
5.7
6.9
6.2
8.4
3.7
4.7
6.3
8.6
13.2

balance-sheet.row.short-term-debt

-2.0305.831.1
20.2
96.8
19
40
19.9
30.1
34
15
18.6
22.5
15
0
0
22
22
7.5
0

balance-sheet.row.tax-payables

28.037.517.212
11.2
9.7
17.2
16.9
22.5
20.2
17.4
17.4
0.9
0.5
0.6
0.1
2.7
3.2
4
0.4
0.2

balance-sheet.row.long-term-debt-total

0000
0
0
0
0
0
0
0
0
0
0
7.5
0
0
0
0
0
0

Deferred Revenue Non Current

1.720.40.50.2
0.2
0.3
0.3
0.5
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

139.12---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

118.6240.247.15.7
3.1
7.4
22.7
5.8
5.9
3.6
6.1
7.6
4.3
4
5
3.5
5.2
0.2
0.1
0.1
9.8

balance-sheet.row.total-non-current-liabilities

140.8435.235.334.9
35
35
35
35.2
34.7
34.7
34.7
34.7
0
0
7.5
0
0
0
0
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

315.9284.6118.2122.9
125.4
192.8
104.2
126.8
114.4
118.3
171.9
109.3
36.2
36
42.4
11.9
8.9
32.9
37.4
26.8
22.9

balance-sheet.row.preferred-stock

54.4527.200
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

2030.04507.5507.5507.5
507.5
507.5
507.5
507.5
507.5
507.5
507.5
253.8
205
205
164
82
82
82
61.5
49.2
45.3

balance-sheet.row.retained-earnings

398.09104.670.326.3
24.9
5
127.2
91.7
326.7
276.6
211.6
158.9
30.1
23.7
55.2
65.3
51.7
39.4
17.4
12.9
3

balance-sheet.row.accumulated-other-comprehensive-income-loss

174.76027.227.2
27.2
27.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

370.71123.7123.4123.4
123.4
123.4
150.6
150.6
150.6
145.6
144.2
397
43
41.8
39.3
94.1
92.6
91.3
3.7
2.3
0.7

balance-sheet.row.total-stockholders-equity

3028.05763728.4684.5
683
663.2
785.4
749.8
984.9
929.7
863.3
809.7
278.1
270.5
258.5
241.4
226.3
212.6
82.6
64.4
49

balance-sheet.row.total-liabilities-and-stockholders-equity

3343.97847.6846.7807.3
808.4
855.9
889.6
876.6
1099.3
1048
1035.3
919
314.2
306.5
300.9
253.3
235.2
245.5
120.1
91.2
71.9

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

3028.05763728.4684.5
683
663.2
785.4
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

3343.97---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

105.9127.129.430.6
58.3
61.9
27.5
26
21.2
16.5
8.8
0
70.4
76.2
54.2
34.5
0
0
0
0
0

balance-sheet.row.total-debt

5.8705.831.1
20.2
96.8
19
40
19.9
30.1
34
15
18.6
22.5
22.5
0
0
22
22
7.5
0

balance-sheet.row.net-debt

-564.95-133.5-178.1-208.3
-122.1
-25.5
-95.9
-42
-53.4
-16.1
0.7
-41.3
-3
12
-7.8
-32.9
-81.9
-131.6
-15.5
-14
-2.4

Cash Flow Statement

The financial landscape of Guangdong Jiaying Pharmaceutical Co., Ltd has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 2.825. The company recently extended its share capital by issuing 0, marking a difference of 0.000 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 44.11 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -51031607.190 in the reporting currency. This is a shift of -1.924 from the previous year. In the same period, the company recorded 25.89, -49.91, and -31.11, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -0.45 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 0, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004

cash-flows.row.net-income

27.3243.91.519.8
-122.2
35.9
-214.8
55.2
66.4
73.7
139.5
7
20.2
25.2
15.1
13.7
24.4
22.1
15.4
2.8

cash-flows.row.depreciation-and-amortization

18.0125.928.428.2
27.2
27.1
26.7
25.7
21.4
23.5
14.9
14.8
14.5
11.9
7.5
6.3
5.4
4.3
4.1
2

cash-flows.row.deferred-income-tax

02.41-0.6
3.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0-2.4-10.6
-3.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

116.01-48.4-4.838.8
-16.1
-6.1
-27.5
-32.1
-46.1
0.7
11.6
-1.4
-14.4
1.1
11.4
-10
-13.3
-0.8
-2.7
3.6

cash-flows.row.account-receivables

118.37-86.59.69
-8.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-2.36-8.4-0.82.5
-4.9
-8.9
-14.5
-2.1
12.6
-4.4
-8.5
-0.3
-7.6
-8.2
-0.7
0.3
-1.4
1.3
2.7
-3.5

cash-flows.row.account-payables

044.1-14.727.9
-6.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

02.41-0.6
3.8
2.8
-13
-30
-58.6
5.1
20.1
-1.1
-6.8
9.3
12.1
-10.3
-11.9
-2.1
-5.3
7.2

cash-flows.row.other-non-cash-items

-48.065.726.710
124.1
5.2
246.1
4.3
0.7
5.5
-146.5
-15.2
-19.5
-18.6
-6
0.6
1.8
0.8
0.8
0.4

cash-flows.row.net-cash-provided-by-operating-activities

113.28000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-12.26-2.7-2.3-11.7
-18.8
-8.9
-18.4
-12
-33.4
-98.7
-8.7
-6.6
-10.8
-35.6
-76.9
-29.1
-8.7
-12.9
-6.1
-18

cash-flows.row.acquisitions-net

141.970.100
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

0-0.100
-86.3
0
-4.3
-2.5
-7
-8.8
0
0
0
0
0
-28.9
0
0
0
0

cash-flows.row.sales-maturities-of-investments

-126.831.632.518.5
0
0
0
0
0
0
5.3
17.8
0
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

-180-49.925.1-25
0
2.2
2.5
0.1
16.3
-15.8
37.1
0
0
0
0
0
0
0
0.1
0

cash-flows.row.net-cash-used-for-investing-activites

-176.93-5155.2-18.2
-105.1
-6.8
-20.2
-14.4
-23.1
-123.2
33.7
11.2
-10.8
-35.6
-76.9
-57.9
-8.7
-12.9
-6
-18

cash-flows.row.debt-repayment

0-31.1-15-135
-19
-58
-19.9
-30.1
-41
-15
-18.6
-22.5
-15
-7.5
0
-22
-22
-15
0
0

cash-flows.row.common-stock-issued

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0-0.5-1-3.8
-3.5
-1.3
-21.9
-1.4
-2.4
-22.2
-7.6
-1.4
-9.8
-9.1
0
-0.5
-1.4
-5.1
0
0

cash-flows.row.other-financing-activites

0031.155
122
37
40
19.9
45.6
26.7
6.6
18.6
15
30
0
-2
129.8
22.6
7.5
6.9

cash-flows.row.net-cash-used-provided-by-financing-activities

0-31.615.1-83.8
99.5
-22.3
-1.8
-11.6
2.2
-10.5
-19.6
-5.4
-9.8
13.4
0
-24.5
106.4
2.6
7.5
6.9

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

-64.89-55.4122.1-5.1
7.4
33
8.6
27.1
21.4
-30.4
33.6
11.1
-19.8
-2.6
-49
-71.7
116
16
19.1
-2.4

cash-flows.row.cash-at-end-of-period

567.95183.9239.3117.2
122.3
114.9
82
73.3
46.2
24.8
55.2
21.6
10.5
30.3
32.9
81.9
153.6
37.5
21.5
2.4

cash-flows.row.cash-at-beginning-of-period

632.85239.3117.2122.3
114.9
82
73.3
46.2
24.8
55.2
21.6
10.5
30.3
32.9
81.9
153.6
37.5
21.5
2.4
4.8

cash-flows.row.operating-cash-flow

113.2827.251.896.9
13
62.1
30.6
53.1
42.3
103.4
19.5
5.3
0.8
19.7
28
10.7
18.3
26.4
17.6
8.8

cash-flows.row.capital-expenditure

-12.26-2.7-2.3-11.7
-18.8
-8.9
-18.4
-12
-33.4
-98.7
-8.7
-6.6
-10.8
-35.6
-76.9
-29.1
-8.7
-12.9
-6.1
-18

cash-flows.row.free-cash-flow

101.0224.449.585.2
-5.9
53.2
12.2
41.1
8.9
4.6
10.7
-1.3
-10
-15.9
-49
-18.3
9.7
13.4
11.5
-9.3

Income Statement Row

Guangdong Jiaying Pharmaceutical Co., Ltd's revenue saw a change of -0.191% compared with the previous period. The gross profit of 002198.SZ is reported to be 347.72. The company's operating expenses are 310.41, showing a change of -17.437% from the last year. The expenses for depreciation and amortization are 25.89, which is a -0.091% change from the last accounting period. Operating expenses are reported to be 310.41, which shows a -17.437% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.248% year-over-year growth. The operating income is 40.52, which shows a -0.248% change when compared to the previous year. The change in the net income is -0.219%. The net income for the last year was 34.32.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004

income-statement-row.row.total-revenue

499.15533.2659.2574.7
544.7
500.5
537
468.1
450
475.8
565.8
226.7
104.5
85.9
75.2
62.3
66.3
64.6
62.7
54.3
37.5

income-statement-row.row.cost-of-revenue

184.54185.5228.5141.9
146.5
106.4
144
125
104.7
126.7
221.3
96.8
52.1
45.1
34.2
25.8
26.9
23.9
24.1
24.6
22

income-statement-row.row.gross-profit

314.61347.7430.7432.8
398.2
394.1
393
343
345.2
349.1
344.6
130
52.4
40.8
41
36.5
39.5
40.7
38.6
29.7
15.5

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

10.47---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

13.37---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

219.49---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-1.19-1.140.746.3
42.9
47.1
0.5
1.1
0
3.9
11.4
4
2
1.2
3.5
2.7
2.6
6.4
1.6
0.5
0.5

income-statement-row.row.operating-expenses

285.61310.4376403.2
365.2
384.6
346.1
304.6
274.5
274.2
263.1
101.2
62
40.7
36.8
28.6
27.4
15.3
14.9
13.5
12.3

income-statement-row.row.cost-and-expenses

470.15495.9604.5545.1
511.7
491
490.1
429.6
379.2
400.9
484.3
198
114.1
85.8
71
54.4
54.2
39.1
39
38.1
34.2

income-statement-row.row.interest-income

2.172.12.32.6
1.1
0.5
0.4
0.3
0.1
0.2
0.3
0.1
0
0.2
0.2
0.3
1.3
0.2
0.2
0
0

income-statement-row.row.interest-expense

000.51
3.7
3.5
1.8
1.8
1.5
2.4
2.2
1.5
1.4
1.6
0.9
0
0.5
1.5
0.3
0.5
0.5

income-statement-row.row.selling-and-marketing-expenses

219.49---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0.142.1-2.8-27.8
-1
-123.1
-4.6
-244.3
-4.1
3.4
5.8
150.5
16.7
20.7
21.9
8.9
3.9
3.3
0.9
-0.8
-0.4

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-1.19-1.140.746.3
42.9
47.1
0.5
1.1
0
3.9
11.4
4
2
1.2
3.5
2.7
2.6
6.4
1.6
0.5
0.5

income-statement-row.row.total-operating-expenses

0.142.1-2.8-27.8
-1
-123.1
-4.6
-244.3
-4.1
3.4
5.8
150.5
16.7
20.7
21.9
8.9
3.9
3.3
0.9
-0.8
-0.4

income-statement-row.row.interest-expense

000.51
3.7
3.5
1.8
1.8
1.5
2.4
2.2
1.5
1.4
1.6
0.9
0
0.5
1.5
0.3
0.5
0.5

income-statement-row.row.depreciation-and-amortization

8.9124.226.628.4
33.5
27.2
27.1
26.7
25.7
21.4
23.5
14.9
14.8
14.5
11.9
7.5
6.3
5.4
4.3
4.1
2

income-statement-row.row.ebitda-caps

30.17---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

33.6540.553.933.6
24.1
8.9
41.8
-206.9
66.7
74.4
76.2
176.3
5
19.6
22.7
14
12.7
23.7
23.1
15.5
2.8

income-statement-row.row.income-before-tax

32.4639.451.15.8
23
-114.2
42.3
-205.8
66.6
78.2
87.3
179.3
7
20.8
26.2
16.8
16.1
28.8
24.6
15.4
2.8

income-statement-row.row.income-tax-expense

5.155.17.24.3
3.2
8
6.5
8.9
11.5
11.9
13.7
39.8
-0.5
0.6
0.9
1.7
2.3
4.4
2.5
0
0.1

income-statement-row.row.net-income

27.3234.343.91.5
19.8
-122.2
35.9
-214.8
55.2
66.4
73.7
139.5
7.6
20.2
25.2
15.1
13.7
24.4
22.1
15.4
2.8

Frequently Asked Question

What is Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ) total assets?

Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ) total assets is 847563113.000.

What is enterprise annual revenue?

The annual revenue is 250417163.000.

What is firm profit margin?

Firm profit margin is 0.630.

What is company free cash flow?

The free cash flow is 0.199.

What is enterprise net profit margin?

The net profit margin is 0.055.

What is firm total revenue?

The total revenue is 0.067.

What is Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ) net profit (net income)?

The net profit (net income) is 34320234.000.

What is firm total debt?

The total debt is 0.000.

What is operating expences number?

The operating expences are 310409681.000.

What is company cash figure?

Enretprise cash is 118503980.000.